WASHINGTON -- Induction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy for patients with moderately to severely active Crohn's disease, topping both ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

In these videos, Sushila Dulal, MD, associate professor of medicine at the University Chicago of Medicine, discusses the latest treatments, state of the pipeline and unmet needs for patients with ...

3 “The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn's disease”, said Mark ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease ... Johnson's Tremfya (guselkumab), and ...

The clearance shores up the competitive position for Omvoh (mirikizumab) in the increasingly competitive inflammatory bowel disease ... (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

subcutaneous guselkumab significantly improves clinical outcomes in patients with ulcerative colitis as well as in those with Crohn’s disease. Medscape Medical News, February 28, 2025 ECC0 2025 ...

3 "The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn's disease”, said Mark Graham, ...

3 “The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn’s disease”, said Mark Graham, ...